• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

    3/10/26 9:29:56 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.'s oldest and most prestigious science and math competition for high school seniors.

    Key Takeaways:

    • This year marks the 85th anniversary of the Science Talent Search and Regeneron's 10th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.

    • Forty finalists were honored at the National Building Museum in Washington, D.C., receiving more than $1.8 million in awards recognizing groundbreaking research, exceptional analytical rigor, exceptional problem-solving skills and potential to shape the future of STEM.



    • Top Three Winners:



      • Connor Hill, 17, of State College, Pennsylvania won first place and $250,000 for discovering a way to identify all the possible "noble polyhedra," highly symmetric shapes with flat sides and straight edges. He wrote a computer program to do the computations and proved there are two infinite families of noble polyhedra, as well as 146 isolated examples.
      • Second place and $175,000 went to Edward Kang, 17, of Hackensack, New Jersey for using retinal images to train AI models on subtle patterns linked to autism and attention-deficit/hyperactivity disorder to create a screening tool called RetinaMind. He also created retinal cell models to study gene changes that may help explain why these differences occur.
      • Third place and $150,000 went to Iris Shen, 17, of The Woodlands, Texas, for testing a potential cancer drug in clams to see if they could serve as an animal model for blood cancer drug discovery. In the clams, the drug had a similar effect to what researchers observe in human cells. She also tested a mix of other potential cancer drugs, which slowed the clams' tumor growth.



    "Congratulations to the winners of this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. "Their bold vision and perseverance reveal what the next generation of problem solvers truly looks like—and why our future is in capable hands. Their creativity, ambition and courage to confront the world's toughest challenges are exactly what this moment demands."

    The Regeneron Science Talent Search is committed to providing a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential, and commitment to creating meaningful impact in crucial STEM fields.

    "Congratulations to the winners of the 2026 Regeneron Science Talent Search, and to all the finalists who participated in this year's competition. These students represent exactly the kind of extraordinary talent scientific progress depends on," said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chairman, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search winner. "From my own experience as a Science Talent Search winner, I know the transformative power of this competition. That's why Regeneron is deepening our commitment and extending our title sponsorship for another decade. Through our support of Science Talent Search and our title sponsorship of the Regeneron International Science Fair, the world's largest high school science competition, we will invest more than $300 million from 2017 to 2036. We may never know where the next great scientific leader will come from, but we do know it's our responsibility to find that talent, fuel it, and give it every chance to change the world."

    Other top honors from the competition include:

    • Fourth Place and $100,000: Rachel Chen, 18, of Los Angeles, California for developing a concrete, visual way to describe systems of many quantum particles using Temperley-Lieb diagrams, expanding on a 1997 finding. Rachel illustrated how a magnetic field influences the entire quantum system using these simple point-and-line diagrams.

    • Fifth Place and $90,000: Jerry Xu, 17, of Lexington, Massachusetts for building an AI program that compresses the features of protein molecules into strings of numbers. He showed that his model enabled a more efficient comparison of protein structure without the loss of important features. This could speed up genetic research and drug discovery.

    • Sixth Place and $80,000: Leanne Fan, 18, of San Diego, California for building a device to simulate microgravity in order to study how wounds heal in space. With the device, she tested red light on injured flatworms and found that it sped up tissue regeneration by 95.2%. She also found that red light treatment speeds up wound repair in human models in normal gravity.

    • Seventh Place and $70,000: Claire Jiang, 18, of Wyckoff, New Jersey for developing a cellular model of juvenile idiopathic arthritis (JIA). She treated cells used to study rheumatoid arthritis with bone morphogenetic protein 4, a protein linked to JIA joint damage. Her experiments showed they acted like JIA cells in their growth and gene expression.
    • Eighth Place and $60,000: Leon Wang, 17, of Stamford, Connecticut, for finding two FDA-approved drugs that may also be effective against Alzheimer's disease. Both drugs reduce the activity of a cellular signaling pathway linked to an Alzheimer's gene. In lab-grown brain cells, the drugs reduced signs of damage due to the pathway.
    • Ninth Place and $50,000: Jonathan Du, 18, of Mountain View, California for investigating the unrestricted finite factorization property. Factorization breaks down mathematical objects into simpler parts. Jonathan's work explores complicated algebraic systems where some elements have several factorizations, and others do not factor at all.
    • Tenth Place and $40,000: Seth Nabat, 18, of Winnetka, California for building a machine learning program to quickly and accurately track particle collisions without sacrificing accuracy by favoring symmetry. Seth's program uses an unconstrained network to catch errors, and another network to find patterns in them.
    • Colin Jie Chu, 18, of Palo Alto, California was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2026. The 40 finalists chose Colin as the person who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society's Board of Trustees for 30 years.
    • The remaining 30 finalists received $25,000 each. In total, Regeneron awarded $3.1 million in awards, including $2,000 to each top scholar and their school. Since the start of Regeneron's sponsorship in 2017 through this year's competition, Regeneron and the Society have engaged and inspired more than 20,000 of the nation's top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes.



    Resources:

    • 2026 Winner Media Kit (photos, bios, research summaries, b-roll, video)
    • Virtual Project Showcase (All 40 finalist projects)
    • Full List of 40 Finalists
    • Top 300 Scholars
    • Notable STS Alumni



    What is the Regeneron Science Talent Search?

    The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States' oldest and most prestigious science and math competition for high school seniors. This year, more than 2,600 students submitted original research in critical scientific fields and were judged by leading experts. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search identifies and supports the U.S.'s most promising future leaders in science as they develop innovative solutions to solve significant global challenges through rigorous research and discoveries. The program provides students with a national stage to present new ideas and challenge conventional ways of thinking.

    For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

    What is Regeneron's role?

    For Regeneron, the Science Talent Search is a deeply personal commitment, as its co-Founders George D. Yancopoulos, M.D., Ph.D. and Leonard S. Schleifer, M.D., Ph.D. began their scientific careers as Science Talent Search participants. In 2017, Regeneron became the third long-term sponsor of the Science Talent Search, succeeding Westinghouse and Intel, with a 10-year, $100 million commitment to help reward and celebrate the best and brightest young minds. Since the beginning of this enduring sponsorship, through this year's Science Talent Search, Regeneron and the Society have engaged and inspired more than 20,000 of the nation's top young scientists, recognized 3,000 as Regeneron Scholars, and awarded over $31 million in prizes. In February 2026, the company renewed its sponsorship for another decade, increasing its investment by 50%, pledging an additional $150 million. Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of the Society and the world's largest high school science competition. Regeneron's support for these two premier programs totals more than $300 million from 2017 to 2036.

    Learn more at https://www.societyforscience.org/regeneron-sts/ or www.regeneron.com/STEM

    What is Society for Science?

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire.

    Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn.

    What is Regeneron?



    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

    Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the United States.

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    Media Contacts:

    Tina Parisi Tuttle, Regeneron

    973-975-9357, [email protected]

    Gayle Kansagor, Society for Science 

    703-489-1131, [email protected]





    Primary Logo

    Get the next $REGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    3/6/2026$923.00Overweight
    Barclays
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    11/24/2025$798.00Buy
    Truist
    11/24/2025$255.00Buy
    HSBC Securities
    11/13/2025$650.00Sector Perform
    Scotiabank
    8/14/2025$890.00Buy
    Rothschild & Co Redburn
    6/30/2025Buy → Hold
    Argus
    More analyst ratings

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Arthur F sold $78,550 worth of shares (100 units at $785.50), decreasing direct ownership by 0.56% to 17,703 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    3/3/26 4:01:53 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zoghbi Huda Y exercised 1,638 shares at a strike of $376.69 and sold $1,279,812 worth of shares (1,638 units at $781.33) (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/23/26 4:55:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP Controller Pitofsky Jason sold $1,585,058 worth of shares (2,036 units at $778.52) and exercised 1,000 shares at a strike of $492.00, decreasing direct ownership by 20% to 4,272 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/11/26 4:03:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Regeneron Pharma with a new price target

    Barclays initiated coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $923.00

    3/6/26 8:35:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma upgraded by BofA Securities with a new price target

    BofA Securities upgraded Regeneron Pharma from Underperform to Buy and set a new price target of $860.00

    1/7/26 8:45:07 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Regeneron Pharma from Overweight to Equal-Weight and set a new price target of $767.00

    12/3/25 8:30:10 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/6/26 5:06:37 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Regeneron Pharmaceuticals Inc.

    10-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/4/26 9:08:38 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    1/30/26 6:51:21 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

    TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.'s oldest and most prestigious science and math competition for high school seniors. Key Takeaways: This year marks the 85th anniversary of the Science Talent Search and Regeneron's 10th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.Forty finalists were honored at t

    3/10/26 9:29:56 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

    Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepatide is a novel dual GLP-1/GIP receptor agonist for which Regeneron has exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau as part of a strateg

    3/9/26 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Investor Conference Presentation

    TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026. The session may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-sc

    3/5/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

    Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe aplastic anemia Regeneron to host virtual ‘Regeneron Roundtable' investor event to discuss its multiple myeloma development program on Wednesday, December 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov.

    11/13/25 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care